315 related articles for article (PubMed ID: 31529722)
1. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice.
Matsuzaka T; Kuba M; Koyasu S; Yamamoto Y; Motomura K; Arulmozhiraja S; Ohno H; Sharma R; Shimura T; Okajima Y; Han SI; Aita Y; Mizunoe Y; Osaki Y; Iwasaki H; Yatoh S; Suzuki H; Sone H; Takeuchi Y; Yahagi N; Miyamoto T; Sekiya M; Nakagawa Y; Ema M; Takahashi S; Tokiwa H; Shimano H
Hepatology; 2020 May; 71(5):1609-1625. PubMed ID: 31529722
[TBL] [Abstract][Full Text] [Related]
2. Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance.
Moon YA; Ochoa CR; Mitsche MA; Hammer RE; Horton JD
J Lipid Res; 2014 Dec; 55(12):2597-605. PubMed ID: 25281760
[TBL] [Abstract][Full Text] [Related]
3. [Role of Fatty Acid Elongase Elovl6 in the Regulation of Fatty Acid Quality and Lifestyle-related Diseases].
Matsuzaka T; Shimano H
Yakugaku Zasshi; 2022; 142(5):473-476. PubMed ID: 35491151
[TBL] [Abstract][Full Text] [Related]
4. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
[TBL] [Abstract][Full Text] [Related]
5. Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity.
Sachithanandan N; Fam BC; Fynch S; Dzamko N; Watt MJ; Wormald S; Honeyman J; Galic S; Proietto J; Andrikopoulos S; Hevener AL; Kay TW; Steinberg GR
Hepatology; 2010 Nov; 52(5):1632-42. PubMed ID: 20799351
[TBL] [Abstract][Full Text] [Related]
6. The effect of LXRα, ChREBP and Elovl6 in liver and white adipose tissue on medium- and long-chain fatty acid diet-induced insulin resistance.
Sun H; Jiang T; Wang S; He B; Zhang Y; Piao D; Yu C; Wu N; Han P
Diabetes Res Clin Pract; 2013 Dec; 102(3):183-92. PubMed ID: 24262945
[TBL] [Abstract][Full Text] [Related]
7. The ketogenic diet prevents steatosis and insulin resistance by reducing lipogenesis, diacylglycerol accumulation and protein kinase C activity in male rat liver.
Jani S; Da Eira D; Stefanovic M; Ceddia RB
J Physiol; 2022 Sep; 600(18):4137-4151. PubMed ID: 35974660
[TBL] [Abstract][Full Text] [Related]
8. Elovl6: a new player in fatty acid metabolism and insulin sensitivity.
Matsuzaka T; Shimano H
J Mol Med (Berl); 2009 Apr; 87(4):379-84. PubMed ID: 19259639
[TBL] [Abstract][Full Text] [Related]
9. Elovl6 promotes nonalcoholic steatohepatitis.
Matsuzaka T; Atsumi A; Matsumori R; Nie T; Shinozaki H; Suzuki-Kemuriyama N; Kuba M; Nakagawa Y; Ishii K; Shimada M; Kobayashi K; Yatoh S; Takahashi A; Takekoshi K; Sone H; Yahagi N; Suzuki H; Murata S; Nakamuta M; Yamada N; Shimano H
Hepatology; 2012 Dec; 56(6):2199-208. PubMed ID: 22753171
[TBL] [Abstract][Full Text] [Related]
10. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.
Raichur S; Brunner B; Bielohuby M; Hansen G; Pfenninger A; Wang B; Bruning JC; Larsen PJ; Tennagels N
Mol Metab; 2019 Mar; 21():36-50. PubMed ID: 30655217
[TBL] [Abstract][Full Text] [Related]
11. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease.
Chen W; Chang B; Li L; Chan L
Hepatology; 2010 Sep; 52(3):1134-42. PubMed ID: 20648554
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of microRNA-125a contributes to obesity-associated insulin resistance and dysregulates lipid metabolism in mice.
Liu R; Wang M; Li E; Yang Y; Li J; Chen S; Shen WJ; Azhar S; Guo Z; Hu Z
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 May; 1865(5):158640. PubMed ID: 31988048
[TBL] [Abstract][Full Text] [Related]
13. Role of fatty acid elongase Elovl6 in the regulation of energy metabolism and pathophysiological significance in diabetes.
Matsuzaka T
Diabetol Int; 2021 Jan; 12(1):68-73. PubMed ID: 33479581
[TBL] [Abstract][Full Text] [Related]
14. Patatin-like phospholipase domain–containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets.
Mitsche MA; Hobbs HH; Cohen JC
J Biol Chem; 2018 May; 293(18):6958-6968. PubMed ID: 29555681
[TBL] [Abstract][Full Text] [Related]
15. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
16. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis.
Kasumov T; Li L; Li M; Gulshan K; Kirwan JP; Liu X; Previs S; Willard B; Smith JD; McCullough A
PLoS One; 2015; 10(5):e0126910. PubMed ID: 25993337
[TBL] [Abstract][Full Text] [Related]
17. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.
Cinar R; Godlewski G; Liu J; Tam J; Jourdan T; Mukhopadhyay B; Harvey-White J; Kunos G
Hepatology; 2014 Jan; 59(1):143-53. PubMed ID: 23832510
[TBL] [Abstract][Full Text] [Related]
18. Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-/-) mouse model.
Kuba M; Matsuzaka T; Matsumori R; Saito R; Kaga N; Taka H; Ikehata K; Okada N; Kikuchi T; Ohno H; Han SI; Takeuchi Y; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Sone H; Yahagi N; Arakawa Y; Fujimura T; Nakagawa Y; Yamada N; Shimano H
Sci Rep; 2015 Dec; 5():17604. PubMed ID: 26619823
[TBL] [Abstract][Full Text] [Related]
19. Perilipin 5 Deletion in Hepatocytes Remodels Lipid Metabolism and Causes Hepatic Insulin Resistance in Mice.
Keenan SN; Meex RC; Lo JCY; Ryan A; Nie S; Montgomery MK; Watt MJ
Diabetes; 2019 Mar; 68(3):543-555. PubMed ID: 30617219
[TBL] [Abstract][Full Text] [Related]
20. Ceramide synthase 6 (CerS6) is upregulated in alcohol-associated liver disease and exhibits sex-based differences in the regulation of energy homeostasis and lipid droplet accumulation.
Jeon S; Scorletti E; Dempsey J; Buyco D; Lin C; Saiman Y; Bayen S; Harkin J; Martin J; Hooks R; Ogretmen B; Argemi J; Melo L; Bataller R; Carr RM
Mol Metab; 2023 Dec; 78():101804. PubMed ID: 37714377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
